Grifulvin V (griseofulvin ultramicrosize) represents a cornerstone in systemic antifungal therapy, specifically formulated to combat dermatophyte infections that are unresponsive to topical treatments. As a microsized preparation, it offers enhanced bioavailability and reliable absorption, making it a clinically validated choice for treating tinea infections affecting the skin, hair, and nails. This oral antifungal works by inhibiting fungal cell division and disrupting hyphal growth, providing a targeted mechanism that supports comprehensive eradication of susceptible organisms. Prescribed for decades, it remains a trusted option within dermatological practice when supervised appropriately.

Features

• Contains griseofulvin ultramicrosize 250 mg or 500 mg per tablet
• Oral administration; available in tablet form
• Derived from Penicillium griseofulvum
• Fungistatic activity against dermatophytes such as Trichophyton, Microsporum, and Epidermophyton
• Requires prescription; not available over-the-counter
• Typically supplied in bottles of 30, 60, or 100 tablets

Benefits

• Effectively eliminates dermatophyte infections from deeper skin layers, hair, and nails
• Reduces risk of recurrence when used for the full prescribed duration
• Helps restore skin, nail, and hair integrity by eradicating the causative fungus
• Avoids the inconvenience and limited efficacy of repeated topical applications in widespread or stubborn infections
• Supported by decades of clinical use and well-understood safety profile under medical supervision
• May prevent spread of infection to other body areas or individuals

Common use

Grifulvin V is indicated for the treatment of ringworm (tinea corporis), athlete’s foot (tinea pedis), jock itch (tinea cruris), barber’s itch (tinea barbae), scalp ringworm (tinea capitis), and nail infections (tinea unguium/onychomycosis) caused by susceptible dermatophytes. It is used when the infection is severe, recurrent, or involves areas not easily treated with topical agents alone.

Dosage and direction

Dosage must be individualized based on infection type, severity, and patient factors. Adults: typically 500 mg daily in single or divided doses; for more severe infections, 1 g daily may be required. Children: approximately 10 mg/kg/day, not to exceed 1 g/day. Administration with a high-fat meal improves absorption. Treatment duration varies—several weeks for skin infections, months for nail infections—and should continue until clinical and laboratory evidence confirms eradication.

Precautions

Periodic monitoring of renal, hepatic, and hematopoietic function is advised during prolonged therapy. Use with caution in patients with porphyria, lupus erythematosus, or penicillin sensitivity (due to cross-sensitivity potential). May cause photosensitivity; advise sun protection. Not recommended during pregnancy or in women planning pregnancy. Effectiveness may be reduced with barbiturates.

Contraindications

Hypersensitivity to griseofulvin or any component of the formulation; porphyria; hepatocellular failure; pregnancy.

Possible side effect

Common: headache, nausea, vomiting, diarrhea, dizziness, insomnia. Less common: photosensitivity reactions, oral thrush, fatigue, peripheral neuropathy, rash, urticaria, proteinuria. Rare: hepatotoxicity, leukopenia, granulocytopenia, systemic lupus erythematosus-like syndrome.

Drug interaction

May decrease effectiveness of oral contraceptives, warfarin; barbiturates may reduce griseofulvin levels. Concurrent use with alcohol may cause tachycardia and flushing. Potentiates effects of depressants like alcohol.

Missed dose

Take as soon as remembered. If close to the next dose, skip the missed dose. Do not double dose.

Overdose

Symptoms may include nausea, vomiting, diarrhea, dizziness, confusion. No specific antidote; treatment is supportive. Contact poison control or seek emergency medical attention.

Storage

Store at room temperature (15–30°C). Keep in original container, tightly closed. Protect from light and moisture. Keep out of reach of children.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized dosage guidance. Do not initiate, adjust, or discontinue Grifulvin V without medical supervision.

Reviews

“Prescribed Grifulvin V for persistent tinea unguium. Noticeable improvement after 3 months. Tolerated well with no significant side effects.” – Dermatology patient, 54
“Used in pediatric tinea capitis cases for years. Reliable, though requires patience and adherence to full course.” – Board-certified dermatologist
“Effective but gastrointestinal side effects were bothersome initially. Taking with food helped.” – Patient, 38
“Go-to option for dermatophyte infections when topicals fail. Requires monitoring but generally safe under supervision.” – Clinical practitioner